Mycobacterium Avium-intracellulare Infection Clinical Trial
OBJECTIVES: I. Determine the bacteriological activity of amithiozone against Mycobacterium
avium complex (MAC) pulmonary disease.
II. Define the ability of amithiozone to improve clinical outcomes in patients with MAC
infection.
III. Determine the safety and tolerance of amithiozone with chronic dosing in these
patients.
IV. Assess the contribution of clarithromycin, streptomycin, rifampin, ethambutol,
kanamycin, and amithiozone in the treatment of pulmonary MAC infection.
PROTOCOL OUTLINE: The is a randomized, open label study. All patients receive a core regimen
of clarithromycin and streptomycin. Patients are randomized into two treatment arms. Arm I
patients receive rifampin and ethambutol. Arm II patients receive amithiozone.
Patients are followed for one year to detect any relapse or other complications.
Patients not eligible for this randomized study may be entered on a short open label study
with amithiozone.
Completion date provided represents the completion date of the grant per OOPD records
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00000883 -
Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy
|
N/A | |
Completed |
NCT00111397 -
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection
|
Phase 1 | |
Completed |
NCT00021567 -
A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections
|
Phase 2 | |
Completed |
NCT00001763 -
Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Avium Complex Infection
|
Phase 1 | |
Recruiting |
NCT05824988 -
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
|
||
Completed |
NCT00001058 -
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
|
Phase 2 | |
Completed |
NCT00000644 -
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS
|
Phase 2 | |
Completed |
NCT00001995 -
A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS
|
N/A | |
Completed |
NCT00001039 -
Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients
|
Phase 2 | |
Completed |
NCT00002192 -
Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.
|
Phase 2 | |
Completed |
NCT00000641 -
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
|
Phase 2 | |
Completed |
NCT00000907 -
A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
|
N/A | |
Completed |
NCT00002080 -
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study
|
N/A | |
Completed |
NCT00002170 -
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
|
Phase 2 | |
Completed |
NCT00001023 -
The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients
|
N/A | |
Completed |
NCT00000860 -
The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients
|
N/A | |
Completed |
NCT00001030 -
The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients
|
Phase 3 | |
Completed |
NCT00000971 -
The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS
|
Phase 1 | |
Completed |
NCT00002140 -
A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients
|
Phase 3 | |
Completed |
NCT00002089 -
An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy
|
N/A |